FYI
AstraZeneca has not began phase 2 of the seamless phase 1/2 clinical trial of AZD0466 yet
It is their next key milestone as indicated in the last update from AstraZeneca
However they are close
A signature payment of US$2 million was paid on execution of the agreement to develop AZD0466.
For the initial product AZD0466, development and launch milestones are worth US$64 million
AstraZeneca commenced a phase 1 clinical trial with AZD0466, triggering the 1st milestone payment to Starpharma of US$3 million
So that leaves us US$61 million to collect
I wonder how much we will receive on initiation of phase 2........ maybe US$10 million
Below is a summary of how milestone payments could play out generally
However with this particular drug.......maybe just maybe the FDA will allow the company to bypass phase 3 and go straight to market
Phase II Start – payment on commencement of a human clinical trial to determine safety and preliminary design of additional efficacy studies;
Phase III Start – payment on commencement of a pivotal human clinical trial;
FDA Filing – payment on filing of a New Drug Application with the FDA;
1st Approval – payment(s) on FDA or other 1st major market approval and/or launch;
EU Filing – payment on filing of a marketing approval application in the EU;
Major EU Approval – payment(s) on EU approval, pricing and/or launch;
Japan+ Filing – payment on filing of a marketing approval application in Japan or other Asia;
Japan+ Approval – payment(s) on Japan or other Asia approval and/or launch;
Other Dev Milestones – typically payments on early R&D, toxicology, development candidate designation or license option exercise;
Deal Size – a summation of all upfront, R&D reimbursement and milestone payments, including Total Dev/Reg milestones, sales milestones and/or milestones for additional products or indications, plus any equity or loan amounts, to be paid to the licensor;
Upfront – the license fee plus any annual payments not based on events (upfront equity was not included, as it is typically based on the fair market value of the securities purchased).
- Forums
- ASX - By Stock
- SPL
- Next key milestone payment
Next key milestone payment
-
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.7¢ |
Change
0.002(2.11%) |
Mkt cap ! $38.76M |
Open | High | Low | Value | Volume |
9.8¢ | 9.8¢ | 9.2¢ | $150.3K | 1.582M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 11175 | 9.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 678 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 11175 | 0.096 |
2 | 265000 | 0.095 |
1 | 227075 | 0.093 |
2 | 68260 | 0.092 |
1 | 50050 | 0.091 |
Price($) | Vol. | No. |
---|---|---|
0.097 | 404 | 2 |
0.098 | 105712 | 4 |
0.099 | 18000 | 1 |
0.100 | 148705 | 4 |
0.105 | 96531 | 4 |
Last trade - 14.35pm 24/07/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online